Agios Pharmaceuticals Inc.
AGIO | NASDAQ
$33.95
+$0.88 (+2.66%)
At close: Sep 21, 2026, 4:00 PM ET
$33.79
-$0.16 (-0.47%)
After-hours:
Sep 21, 2026, 7:30 PM ET
Company Profile
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.
Key Executives
| Name | Position |
|---|---|
| Brian Goff | Chief Executive Officer & Director |
| Cecilia Jones | Chief Financial Officer |
| James William Burns | Chief Legal Officer |
| Craig Thompson | Co-Founder |
| Krishnan Viswanadhan | Chief Strategy & Operations Officer |
| Lewis Clayton Cantley | Co-Founder |
| Sarah Gheuens | Chief Medical Officer and Head of Research & Development |
| Shin-San Su | Co-Founder |
| T. J. Washburn | Vice President, Controller & Principal Accounting Officer |
| Tak Wah Mak FRSC | Co-Founder |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 06, 2026 | 4 | Filing |
| Aug 03, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Jul 30, 2026 | 10-Q | Quarterly Report |
| Jul 30, 2026 | 8-K | Current Report |
| Jul 10, 2026 | 4 | Filing |
| Jul 02, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Jul 02, 2026 | 4 | Filing |
| Jun 23, 2026 | 4 | Filing |
| Jun 23, 2026 | 4 | Filing |
| Jun 23, 2026 | 4 | Filing |
Agios Pharmaceuticals Inc.
| Country | United States |
| IPO Date | Jul 23, 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 540 |
| CEO | Brian Goff |
Contact Details
88 Sidney Street Cambridge,
Massachusetts 02139 United States
Stock Details
| Ticker Symbol | AGIO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001439222 |
| CUSIP Number | 00847X104 |
| ISIN Number | US00847X1046 |
| SIC Code | 2834 |
Recent News
- 1 month ago / seekingalpha.comAgios Pharmaceuticals: Indication Stacking Is Creating A Commercial Flywheel
- 1 month ago / prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
- 2 months ago / zacks.comAGIO Q2 Earnings Beat Estimates, Revenues Increase Year Over Year
- 2 months ago / seekingalpha.comAgios Pharmaceuticals, Inc. (AGIO) Q2 2026 Earnings Call Transcript
- 2 months ago / marketbeat.comAgios Pharmaceuticals Q2 Earnings Call Highlights
- 2 months ago / zacks.comAgios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates
- 2 months ago / globenewswire.comAgios Reports Second Quarter 2026 Financial Results and Provides Business Update
- 2 months ago / zacks.comAgios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
- 2 months ago / zacks.comAGIO Shares Sink Nearly 7% After Scrapping the Tebapivat SCD Program
- 2 months ago / benzinga.comAgios Reports Neutral Sickle Cell Data, Decides To Stop Development
Add to Watchlist
Select watchlists to add or remove AGIO